--- - |2 Summary Epigallocatechin‐3‐gallate (EGCG), a major polyphenolic constituent of green tea, possesses remarkable chemopreventive and therapeutic potential against various types of cancer, including leukaemia. However, the molecular mechanism involved in chronic myeloid leukaemia (CML), especially imatinib‐resistant CML cells, is not completely understood. In the present study, we investigated the effect of EGCG on the growth of Bcr/Abl+ CML cell lines, including imatinib‐resistant cell lines and primary CML cells. The results revealed that EGCG could inhibit cell growth and induce apoptosis in CML cells. The mechanisms involved inhibition of the Bcr/Abl oncoprotein and regulation of its downstream p38‐MAPK/JNK and JAK2/STAT3/AKT pathways. In conclusion, we documented the anti‐CML effects of EGCG in imatinib‐sensitive and imatinib‐resistant Bcr/Abl+ cells, especially T315I‐mutated cells. - 'Clinical and Experimental Pharmacology and Physiology, EarlyView. '